Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 112

1.

Core outcome measures for opioid abuse liability laboratory assessment studies in humans: IMMPACT recommendations.

Comer SD, Zacny JP, Dworkin RH, Turk DC, Bigelow GE, Foltin RW, Jasinski DR, Sellers EM, Adams EH, Balster R, Burke LB, Cerny I, Colucci RD, Cone E, Cowan P, Farrar JT, Haddox JD, Haythornthwaite JA, Hertz S, Jay GW, Johanson CE, Junor R, Katz NP, Klein M, Kopecky EA, Leiderman DB, McDermott MP, O'Brien C, O'Connor AB, Palmer PP, Raja SN, Rappaport BA, Rauschkolb C, Rowbotham MC, Sampaio C, Setnik B, Sokolowska M, Stauffer JW, Walsh SL.

Pain. 2012 Dec;153(12):2315-24. doi: 10.1016/j.pain.2012.07.035. Epub 2012 Sep 19.

2.

Long-term opioid therapy, aberrant behaviors, and substance misuse: comparison of patients treated by resident and attending physicians in a general medical clinic.

Colburn JL, Jasinski DR, Rastegar DA.

J Opioid Manag. 2012 May-Jun;8(3):153-60. doi: 10.5055/jom.2012.0111.

PMID:
22798175
3.

Buprenorphine maintenance treatment in a primary care setting: outcomes at 1 year.

Soeffing JM, Martin LD, Fingerhood MI, Jasinski DR, Rastegar DA.

J Subst Abuse Treat. 2009 Dec;37(4):426-30. doi: 10.1016/j.jsat.2009.05.003. Epub 2009 Jun 23.

PMID:
19553061
4.

Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse.

Jasinski DR, Krishnan S.

J Psychopharmacol. 2009 Jun;23(4):419-27. doi: 10.1177/0269881109103113. Epub 2009 Mar 27.

PMID:
19329547
5.

Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers.

Jasinski DR, Krishnan S.

J Psychopharmacol. 2009 Jun;23(4):410-8. doi: 10.1177/0269881108093841. Epub 2008 Jul 17.

PMID:
18635707
6.

Dosing adjustments in postpartum patients maintained on buprenorphine or methadone.

Jones HE, Johnson RE, O'Grady KE, Jasinski DR, Tuten M, Milio L.

J Addict Med. 2008 Jun;2(2):103-7. doi: 10.1097/ADM.0b013e31815ca2c6.

PMID:
21768979
7.

Abuse liability assessment of atomoxetine in a drug-abusing population.

Jasinski DR, Faries DE, Moore RJ, Schuh LM, Allen AJ.

Drug Alcohol Depend. 2008 May 1;95(1-2):140-6. doi: 10.1016/j.drugalcdep.2008.01.008. Epub 2008 Mar 6.

PMID:
18328639
8.

Buprenorphine and norbuprenorphine in hair of pregnant women and their infants after controlled buprenorphine administration.

Goodwin RS, Wilkins DG, Averin O, Choo RE, Schroeder JR, Jasinski DR, Johnson RE, Jones HE, Huestis MA.

Clin Chem. 2007 Dec;53(12):2136-43. Epub 2007 Oct 5.

PMID:
17921260
9.

Increased occupancy of dopamine receptors in human striatum during cue-elicited cocaine craving.

Wong DF, Kuwabara H, Schretlen DJ, Bonson KR, Zhou Y, Nandi A, Brasić JR, Kimes AS, Maris MA, Kumar A, Contoreggi C, Links J, Ernst M, Rousset O, Zukin S, Grace AA, Lee JS, Rohde C, Jasinski DR, Gjedde A, London ED.

Neuropsychopharmacology. 2006 Dec;31(12):2716-27. Epub 2006 Sep 13. Erratum in: Neuropsychopharmacology. 2007 Jan;32(1):256. Lee, Jae Sung [added].

10.

Development and preliminary experience with an ease of extractability rating system for prescription opioids.

Katz NP, Buse DC, Budman SH, Wing Venuti S, Fernandez KC, Benoit C, Bianchi R, Cooper D, Jasinski DR, Smith DE, Butler SF.

Drug Dev Ind Pharm. 2006 Jul;32(6):727-46.

PMID:
16885128
11.
12.
13.

A resident clerkship that combines inpatient and outpatient training in substance abuse and HIV care.

Rastegar DA, Fingerhood MI, Jasinski DR.

Subst Abus. 2004 Dec;25(4):11-5.

PMID:
16172088
14.

Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome.

Jones HE, Johnson RE, Jasinski DR, O'Grady KE, Chisholm CA, Choo RE, Crocetti M, Dudas R, Harrow C, Huestis MA, Jansson LM, Lantz M, Lester BM, Milio L.

Drug Alcohol Depend. 2005 Jul;79(1):1-10.

PMID:
15943939
15.

Randomized controlled study transitioning opioid-dependent pregnant women from short-acting morphine to buprenorphine or methadone.

Jones HE, Johnson RE, Jasinski DR, Milio L.

Drug Alcohol Depend. 2005 Apr 4;78(1):33-8.

PMID:
15769555
16.

Highly active antiretroviral therapy outcomes in a primary care clinic.

Rastegar DA, Fingerhood MI, Jasinski DR.

AIDS Care. 2003 Apr;15(2):231-7.

PMID:
12856344
17.

A Comparison of Clonidine and Buprenorphine in the Outpatient Treatment of Opiate Withdrawal.

Fingerhood MI, Thompson MR, Jasinski DR.

Subst Abus. 2001 Sep;22(3):193-199.

PMID:
12466679
18.

One-, three-, and six-month outcomes after brief inpatient opioid detoxification.

Chutuape MA, Jasinski DR, Fingerhood MI, Stitzer ML.

Am J Drug Alcohol Abuse. 2001 Feb;27(1):19-44.

PMID:
11373035
19.

Buprenorphine treatment of pregnant opioid--dependent women: maternal and neonatal outcomes.

Johnson RE, Jones HE, Jasinski DR, Svikis DS, Haug NA, Jansson LM, Kissin WB, Alpan G, Lantz ME, Cone EJ, Wilkins DG, Golden AS, Huggins GR, Lester BM.

Drug Alcohol Depend. 2001 Jun 1;63(1):97-103.

PMID:
11297835
20.

Evaluation of the abuse liability of modafinil and other drugs for excessive daytime sleepiness associated with narcolepsy.

Jasinski DR, Kovacević-Ristanović R.

Clin Neuropharmacol. 2000 May-Jun;23(3):149-56. Review.

PMID:
10895398
21.
22.

Abuse potential of morphine/dextromethorphan combinations.

Jasinski DR.

J Pain Symptom Manage. 2000 Jan;19(1 Suppl):S26-30.

24.

Cocaine effects on digital blood flow and diffusing capacity for carbon monoxide among chronic cocaine users.

Sullivan JT, Becker PM, Preston KL, Wise RA, Wigely FM, Testa MP, Jasinski DR.

Am J Med. 1997 Mar;102(3):232-8.

PMID:
9217590
25.

Abuse liability of testosterone.

Fingerhood MI, Sullivan JT, Testa M, Jasinski DR.

J Psychopharmacol. 1997;11(1):59-63.

PMID:
9097895
26.

Tolerance and dependence to opiates.

Jasinski DR.

Acta Anaesthesiol Scand. 1997 Jan;41(1 Pt 2):184-6. Review.

PMID:
9061104
27.

Ritanserin in the treatment of alcohol dependence--a multi-center clinical trial. Ritanserin Study Group.

Johnson BA, Jasinski DR, Galloway GP, Kranzler H, Weinreib R, Anton RF, Mason BJ, Bohn MJ, Pettinati HM, Rawson R, Clyde C.

Psychopharmacology (Berl). 1996 Nov;128(2):206-15.

PMID:
8956382
28.

5-HT3 receptor antagonism and psychoactivity.

Sullivan JT, Preston KL, Testa MP, Bell J, Jasinski DR.

J Psychopharmacol. 1996 Jan;10(3):182-7. doi: 10.1177/026988119601000302.

PMID:
22302943
29.

Buprenorphine reduces cerebral glucose metabolism in polydrug abusers.

Walsh SL, Gilson SF, Jasinski DR, Stapleton JM, Phillips RL, Dannals RF, Schmidt J, Preston KL, Grayson R, Bigelow GE, et al.

Neuropsychopharmacology. 1994 May;10(3):157-70.

30.

Psychopharmacology and abuse potential of transnasal butorphanol.

Preston KL, Sullivan JT, Testa M, Jasinski DR.

Drug Alcohol Depend. 1994 Apr;35(2):159-67.

PMID:
8055737
31.

Single-dose pharmacodynamics of diazepam and pentobarbital in substance abusers.

Sullivan JT, Jasinski DR, Johnson RE.

Clin Pharmacol Ther. 1993 Dec;54(6):645-53.

PMID:
8275619
32.

Prevalence of hepatitis C in a chemically dependent population.

Fingerhood MI, Jasinski DR, Sullivan JT.

Arch Intern Med. 1993 Sep 13;153(17):2025-30.

PMID:
8357288
33.

Psychoactivity and abuse potential of sumatriptan.

Sullivan JT, Preston KL, Testa MP, Busch M, Jasinski DR.

Clin Pharmacol Ther. 1992 Dec;52(6):635-42.

PMID:
1333934
34.

History of abuse liability testing in humans.

Jasinski DR.

Br J Addict. 1991 Dec;86(12):1559-62.

PMID:
1786487
35.

Abuse liability studies of opioid agonist-antagonists in humans.

Preston KL, Jasinski DR.

Drug Alcohol Depend. 1991 Jun;28(1):49-82. Review.

PMID:
1884671
36.

Intravenous methylphenidate abuse. Prototype for prescription drug abuse.

Parran TV Jr, Jasinski DR.

Arch Intern Med. 1991 Apr;151(4):781-3.

PMID:
1849397
37.

Abuse potential and pharmacological comparison of tramadol and morphine.

Preston KL, Jasinski DR, Testa M.

Drug Alcohol Depend. 1991 Jan;27(1):7-17.

PMID:
2029860
38.

Relative abuse liability and pharmacodynamics of transnasal and intramuscular butorphanol.

Sullivan JT, Preston KL, Testa MP, Jasinski DR.

NIDA Res Monogr. 1990;105:452. No abstract available.

PMID:
1876073
39.

Evaluation of the 5HT3 antagonist ondansetron (O) for cocaine (C)-like activity and abuse potential.

Jasinski DR, Preston KL, Testa M, Sullivan JT.

NIDA Res Monogr. 1990;105:515. No abstract available.

PMID:
1831542
40.

Learning disabilities in alcohol-dependent adults: a preliminary study.

Rhodes SS, Jasinski DR.

J Learn Disabil. 1990 Nov;23(9):551-6.

PMID:
2250135
41.

Sublingual versus subcutaneous buprenorphine in opiate abusers.

Jasinski DR, Fudala PJ, Johnson RE.

Clin Pharmacol Ther. 1989 May;45(5):513-9.

PMID:
2721107
42.

Effects of tramadol in humans: assessment of its abuse potential.

Preston KL, Jasinski DR.

NIDA Res Monogr. 1989;95:392. No abstract available.

PMID:
2701307
43.

Evaluation of the abuse potential of picenadol.

Jasinski DR, Preston KL.

NIDA Res Monogr. 1989;95:387. No abstract available.

PMID:
2641005
44.

Human abuse liability assessment by measurement of subjective and physiological effects.

Jasinski DR, Henningfield JE.

NIDA Res Monogr. 1989;92:73-100. Review. No abstract available.

PMID:
2512504
45.

Naloxone fails to alter local cerebral glucose utilization in the rat.

Fanelli RJ, Walovitch RC, Jasinski DR, London ED.

Pharmacol Biochem Behav. 1988 Oct;31(2):481-5.

PMID:
3244723
46.

Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans.

Bickel WK, Stitzer ML, Bigelow GE, Liebson IA, Jasinski DR, Johnson RE.

J Pharmacol Exp Ther. 1988 Oct;247(1):47-53.

PMID:
2459370
47.

The psychopharmacologic and prolactin response after large doses of naloxone in man.

Kumor KM, Haertzen CA, Jasinski DR, Johnson RE.

Pharmacol Biochem Behav. 1988 Aug;30(4):967-75.

PMID:
3227043
48.

Pharmacologic basis for nicotine replacement.

Henningfield JE, Jasinski DR.

Prog Clin Biol Res. 1988;261:35-61. Review. No abstract available.

PMID:
3289010
49.

Conceptual basis of replacement therapies for chemical dependence.

Jasinski DR, Henningfield JE.

Prog Clin Biol Res. 1988;261:13-34. Review. No abstract available.

PMID:
3289002
50.

A clinical trial of buprenorphine: comparison with methadone in the detoxification of heroin addicts.

Bickel WK, Stitzer ML, Bigelow GE, Liebson IA, Jasinski DR, Johnson RE.

Clin Pharmacol Ther. 1988 Jan;43(1):72-8.

PMID:
3275523

Supplemental Content

Loading ...
Support Center